(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 March 2013 (28.03.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/043933 A3

(51) **International Patent Classification**:
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01) *A61P 37/00* (2006.01)

(21) **International Application Number**:
PCT/US2012/056429

(22) **International Filing Date**:
20 September 2012 (20.09.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/538,024 22 September 2011 (22.09.2011) US

(71) **Applicant** *(for all designated States except US)*: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) **Inventors; and**
(71) **Applicants** *(for US only)*: **DELANEY, John M.** [US/US]; 4660 95th Avenue NE, Bellevue, Washington 98004 (US). **FANSLOW, William Christian, III** [US/US]; 18425 8th Avenue SW, Normandy Park, Washington 98166 (US). **KING, Chadwick Terence** [CA/CA]; 1325 Moody Avenue, North Vancouver, British Columbia V7L 3T5 (CA).

(74) **Agent**: **RAMOS, Robert T.**; Amgen Inc., Patent Operations, M.S. 28-2-C, One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) **Title**: CD27L ANTIGEN BINDING PROTEINS

	Epitope Bin	Affinity Hu Biacore K_D nM	Native cell Avidity EC50 nM	Cyno Avidity EC50 nM	ADCC EC50 nM	ADCP EC50 pM	CDC # EC50 nM	Internalization T ½ (hr)
Chimeric mouse anti-human CD27L	3	1.25	0.60	2.22	0.195	2.17	2.64	0.41
Ab1	1	0.62	0.32	0.05	0.021	1.12	1.0	1.03
Ab2	1	0.59	0.24	0.24	0.034	1.19	1.17	0.69
Ab3	1	4.35	4.18	2.80	0.715	64.8	10.6	0.49
Ab4	3	3.05	0.25	0.48	0.332	1.55	1.54	0.30
Ab5	2	10.4	0.66	1.40	0.422	2.36	5.28	0.75
Ab6	4	6.06	0.87	0.87	0.167	1.88	4.20	1.08
Ab7	4	0.71	0.18	0.43	0.076	0.80	0.64	0.43
Ab8	2	10.8	0.09	0.34	> 67	1.60	> 67	1.81

FIG. 1

(57) **Abstract**: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.

WO 2013/043933 A3

WO 2013/043933 A3

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
30 May 2013